-
1Academic Journal
Συγγραφείς: Ризаева Мехрибан Ахмадовнa
Πηγή: SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES; Vol. 3 No. 5 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 552-555 ; НАУЧНЫЙ ЖУРНАЛ ПРИКЛАДНЫХ И МЕДИЦИНСКИХ НАУК; Том 3 № 5 (2024): AMALIY VA TIBBIYOT FANLARI ILMIY JURNALI; 552-555 ; 2181-3469
Θεματικοί όροι: коронарное шунтирование, сахарный диабет, пероральные сахароснижающие препараты, инсулин
Περιγραφή αρχείου: application/pdf
-
2Academic Journal
Συγγραφείς: Bondar, M.V., Pylypenko, M.M., Halushko, O.A., Ovsiyenko, T.V.
Πηγή: EMERGENCY MEDICINE; № 2.97 (2019); 25-34
МЕДИЦИНА НЕОТЛОЖНЫХ СОСТОЯНИЙ; № 2.97 (2019); 25-34
МЕДИЦИНА НЕВІДКЛАДНИХ СТАНІВ; № 2.97 (2019); 25-34Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, сахарный диабет, инсулин, глюкагон, сахароснижающие препараты, гипогликемия, скрытая гипогликемия, ночная гипогликемия, медикаментозно- обусловленная гипогликемия, цукровий діабет, інсулін, цукрознижувальні препарати, гіпоглікемія, прихована гіпоглікемія, нічна гіпоглікемія, медикаментозно-зумовлена гіпоглікемія, diabetes mellitus, insulin, glucagon, hypoglycaemic drugs, hypoglycaemia, latent hypoglycaemia, nocturnal hypoglycaemia, drug-induced hypoglycaemia, 3. Good health
Περιγραφή αρχείου: application/pdf
-
3Academic Journal
Συγγραφείς: Tsubanova, N. A., Berdnyk, O. H.
Πηγή: Clinical pharmacy; Vol. 24 No. 1 (2020); 06-13
Клиническая фармация; Том 24 № 1 (2020); 06-13
Клінічна фармація; Том 24 № 1 (2020); 06-13
Клінічна фармація; Том 24, № 1 (2020); 06-13
Clinical pharmacy; Том 24, № 1 (2020); 06-13
Клиническая фармация; Том 24, № 1 (2020); 06-13Θεματικοί όροι: experimental pharmacology, diabetes mellitus type 2, глібенкламід, complex hypoglycemic drugs, цукровий діабет 2 типу, УДК 615.015, сахарный диабет 2 типа, комплексные сахароснижающие препараты, експериментальна фармакологія, комплексні цукрознижувальні препарати, UDC 615.015:615.272.3:615.272.4, UDC 615.015, 3. Good health, УДК 615.015:615.272.3:615.272.4, 03 medical and health sciences, 0302 clinical medicine, glibenclamide, экспериментальная фармакология, 615.272.3, 615.272.4, глибенкламид
Περιγραφή αρχείου: application/pdf
-
4Academic Journal
Συγγραφείς: Zh. D. Kobalava, G. К. Kiyakbaev
Πηγή: Российский кардиологический журнал, Vol 0, Iss 8, Pp 79-91 (2018)
Russian Journal of CardiologyΘεματικοί όροι: diabetes type 2, sglt2 inhibitor (gliflozin), cardiovascular complications, glucose lowering therapy, heart failure, сердечная недостаточность, сахароснижающие препараты, сахарный диабет 2 типа, SGLT2 inhibitor (gliflozin), 3. Good health, 03 medical and health sciences, 0302 clinical medicine, RC666-701, Diseases of the circulatory (Cardiovascular) system, ингибиторы SGLT2 (глифлозины), сердечно-сосудистые осложнения
Σύνδεσμος πρόσβασης: https://russjcardiol.elpub.ru/jour/article/download/2918/2383
https://doaj.org/article/91a10030bf044459ade6e9e89263592c
https://openrepository.ru/article?id=246482
https://cyberleninka.ru/article/n/saharnyy-diabet-2-tipa-i-serdechno-sosudistye-oslozhneniya-mozhno-li-uluchshit-prognoz-naznacheniem-saharosnizhayuschih-preparatov
https://russjcardiol.elpub.ru/jour/article/viewFile/2918/2383
https://cyberleninka.ru/article/n/saharnyy-diabet-2-tipa-i-serdechno-sosudistye-oslozhneniya-mozhno-li-uluchshit-prognoz-naznacheniem-saharosnizhayuschih-preparatov/pdf
https://russjcardiol.elpub.ru/jour/article/view/2918 -
5Academic Journal
Συγγραφείς: Kobalava Z.D., Kiyakbaev G.K.
Πηγή: Russian Journal of Cardiology
Θεματικοί όροι: diabetes type 2, cardiovascular complications, heart failure, SGLT2 inhibitor (gliflozin), glucose lowering therapy, сахарный диабет 2 типа, сердечно-сосудистые осложнения, сердечная недостаточность, сахароснижающие препараты, ингибиторы SGLT2 (глифлозины)
Relation: https://doi.org/10.15829/1560-4071-2018-8-79-91; https://openrepository.ru/article?id=246482
Διαθεσιμότητα: https://openrepository.ru/article?id=246482
-
6Academic Journal
Συγγραφείς: A. K. Ovsyannikova, M. V. Ryabets, O. D. Rymar, А. К. Овсянникова, М. В. Рябец, О. Д. Рымар
Πηγή: Meditsinskiy sovet = Medical Council; № 7 (2020); 26-31 ; Медицинский Совет; № 7 (2020); 26-31 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2020-7
Θεματικοί όροι: мутации, continuous glucose monitoring, glycemic variability, sugar-lowering drugs, glycemia, mutations, непрерывное мониторирование глюкозы, вариабельность гликемии, сахароснижающие препараты, гликемия
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/5652/5151; Дедов И.И., Шестакова М.В., Майоров А.Ю. (ред.) Алгоритмы специали- зированной медицинской помощи больным сахарным диабетом. 8-й вып. Сахарный диабет. 2017;20(1S). doi:10.14341/DM20171S8.; Ovsyannikova A.K., Rymar O.D., Ivanoshchuk D.E., Mikhailova S.V., Shakhtshneider E.V., Orlov P.S. et al. A case of maturity onset diabetes of the young (MODY3) in a family with a novel HNF1A gene mutation in five generations. Diabetes therapy. 2018;9(1):413–420. doi:10.1007/s13300-017-0350-8.; Kleinberger J.W., Pollin T.I. Undiagnosed MODY: Time for action. Curr Diab Rep. 2015;15(12):110. doi:10.1007/s11892-015-0681-7.; Shields B.M., Hicks S., Shepherd M.H., Colclough K., Hattersley A.T., Ellard S. Maturity-onset diabetes of the young (MODY): how many cases are we missing? Diabetologia. 2010;53(12):2504–2508. doi:10.1007/s00125-010-1799-4.; Овсянникова А.К. Генетические характеристики диабета MODY 2 в Сибири. Бюллетень Сибирского отделения Российской академии медицинских наук. 2013;33(5):74–77. Режим доступа: http://sibmed.net/article.php?lang=eng&id_article=240.; Rubio-Cabezas O., Hattersley A.T., Njølstad P.R., Mlynarski W., Ellard S., White N. et al. ISPAD Clinical Practice Consensus Guidelines 2014. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatric Diabetes. 2014;15(20):47–64. doi:10.1111/pedi.12192.; Nyunt O., Wu J.Y., McGown I.N., Harris M., Huynh T., Leong G.M. et al. Investigating Maturity Onset Diabetes of the Young. Clin Biochem Rev. 2009;30(2):67–74. Available at: https://pubmed.ncbi.nlm.nih.gov/19565026-investigating-maturity-onset-diabetes-of-the-young/; Зубкова Н.А., Гиоева О.А., Тихонович Ю.В., Петров В.М., Васильев Е.В., Тюльпаков А.Н., Дедов И.И. Персонализация коррекции нарушений углеводного обмена с учетом генотипа у пациентов с сахарным диабетом типа MODY, обусловленного мутациями в генах GCK, HNF1A, HNF4A. World Journal of Personalized Medicine. 2017;1(1):40–48. doi:10.14341/WJPM9298.; Кураева Т.Л., Сечко Е.А., Зильберман Л.И., Иванова О.Н., Майоров А.Ю., Кокшарова Е.О. Петеркова В.А., Дедов И.И. Молекулярно-генетические и клинические варианты MODY2 и MODY3 у детей в России. Проблемы эндокринологии. 2015;61(5):14–25. doi:10.14341/probl201561514-25.; Covanțev S., Chiriac A., Perciuleac L., Zozina V. Maturity onset diabetes of the young: Diagnosis and treatment options. Russian Open Medical Journal. 2016;5(4):e0402. doi:10.15275/rusomj.2016.0402.; Heuvel-Borsboom H., Valk H.W., Losekoot M., Westerink J. Maturity onset diabetes of the young: Seek and you will find. The Netherlands Journal of Medicine. 2016;74(5):193–200. Available at: http://www.njmonline.nl/getpdf.php?id=1716.; Воевода М.И., Шахтшнейдер Е.В., Рымар О.Д., Овсянникова А.К., Воропаева О.Д., Иванощук Д.Е. и др. Молекулярная генетика и клиника MODY диабета. Новосибирск: Изд-во СО РАН; 2017. 164 с. Режим доступа: https://www.sibran.ru/catalog/BIO/169543.; Петеркова В.А., Кураева Т.Л., Прокофьев С.А., Емельянов А.О., Захарова Е.Ю., Цыганкова П.Г., Гришина Д.П. Молекулярная генетика и клинические осо- бенности моногенных форм сахарного диабета. Вестник Российской академии медицинских наук. 2012;67(1):81–86. doi:10.15690/vramn.v67i1.115.; Brunerova L., Rahelić D., Ceriello A., Broz J. Use of oral antidiabetic drugs in the treatment of maturity‐onset diabetes of the young: A mini review. Diabetes Metab Res Rev. 2018;34(1):e2940. doi:10.1002/dmrr.2940.; Raile K., Schober E., Konrad K., Thon A., Grulich-Henn J., Meissner T. et al. Treatment of young patients with HNF1A mutations (HNF1A‐MODY). Diabet Med. 2015;32(4):526–530. doi:10.1111/dme.12662.; Laver T.W., Colclough K., Shepherd M., Patel K., Houghton J.A.L., Dusatkova P. et al. The common p.R114W HNF4A mutation causes a distinct clinical subtype of monogenic diabetes. Diabetes. 2016;65(10):3212–3217. doi:10.2337/db16-0628.; Kusunoki E., Hidenori K., Kusano M., Teranishi R., Shibuya H., Okada T. Continuous Interstitial Subcutaneous Fluid Glucose (ISFG) Measurement during Pre- and Intraoperative Periods for Highly Invasive Surgery. Masui. 2016;65(3):281–287. (In Japanese) Available at: https://www.ncbi.nlm.nih.gov/pubmed/27097509.; Polsky S., Garcetti R. CGM, Pregnancy, and Remote Monitoring. Diabetes Technol Ther. 2017;19(S3):S49–S59. doi:10.1089/dia.2017.0023.; Кривко А.А., Мельниченко Г.А., Кузнецов Н.С., Трошина Е.А., Дедов И.И. Современные технологии в диагностике и лечении инсулиномы. Проблемы эндокринологии. 2013;59(5):36–41. doi:10.14341/probl201359536-41.; Gu W., Liu Y., Liu H., Yang G., Guo Q., Du J. et al. Characteristics of Glucose Metabolism Indexes and Continuous Glucose Monitoring System (CGMS) in Patients with Insulinoma. Diabetol Metab Syndr. 2017;9:17. doi:10.1186/s13098-017-0215-3.; Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете. Новосибирск: ИПЦ НГУ; 2016. 251 c.; Климонтов В.В., Мякина Н.Е. Вариабельность гликемии при сахарном диабете: инструмент для оценки качества гликемического контроля и риска осложнений. Сахарный диабет. 2014;17(2):76–82. doi:10.14341/DM2014276-82.; Klimontov V.V., Myakina N.E. Glucose variability indices predict the episodes of nocturnal hypoglycemia in elderly type 2 diabetic patients treated with insulin. Diabetes Metab Syndr. 2017;11(2):119–124. doi:10.1016/j.dsx.2016.08.023.; Tang L., Ye H., Hong Q., Wang L., Wang Q., Wang H. et al. Elevated CpG island methylation of GCK gene predicts the risk of type 2 diabetes in Chinese males. Gene. 2014;547(2):329–333. doi:10.1016/j.gene.2014.06.062.; Negahdar M., Aukrust I., Molnes J., Solheim M.H., Johansson B.B., Sagen J.V. et al. GCK-MODY diabetes as a protein misfolding disease: the mutation R275C promotes protein misfolding, self-association and cellular degra dation. Mol Cell Endocrinol. 2014;382(1):55–65. doi:10.1016/j.mce.2013.08.020.; Thanabalasingham G., Kaur K., Talbot F., Colclough K., Mathews A., Taylor J. et al. Atypical phenotype associated with reported GCK exon 10 deletions: clinical judgement is needed alongside appropriate genetic investigations. Diabet Med. 2013;30(8):e233–e238. doi:10.1111/dme.12210.; Steele A.М., Wensley K.J., Ellard S., Murphy R., Shepherd M., Colclough K. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: Observational case control studies. Plos One. 2013;8(6):e65326. doi:10.1371/journal.pone.0065326.; Lachance C.-H. Practical Aspects of Monogenic Diabetes: A Clinical Point of View. Can J Diabetes. 2016;40(5):368–375. doi:10.1016/j.jcjd.2015.11.004.; Timsit J., Saint-Martin C., Dubois-Laforgue D., Bellanné-Chantelot C. Searching for Maturity-Onset Diabetes of the Young (MODY): When and What for? Can J Diabetes. 2016;40(5):455–461. doi:10.1016/j.jcjd.2015.12.005.; Pihoker C., Gilliam L., Ellard S., Dabelea D., Davis C., Dolan L.M. et al. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the search for diabetes in youth. JCEM. 2013;98(10):4055–4062. doi:10.1210/jc.2013-1279.; Pearson E.R., Starkey B.J., Powell R.J., Gribble F., Clark P.M., Hattersley A.T. Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet. 2003;362(9392):1275–1281. doi:10.1016/S0140-6736(03)14571-0.; Østoft S.H., Bagger J.I., Hansen T., Pedersen O., Faber J., Holst J.J. et al. Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: A double-blind, randomized, crossover trial. Diabetes Care. 2014;37(7):1797–1805. doi:10.2337/dc13-3007.; Lumb A.N., Gallen I.W. Treatment of HNF1-alpha MODY with the DPP-4 inhibitor sitagliptin(1). Diabet Med. 2009;26(2):189–190. doi:10.1111/j.1464-5491.2008.02645.x.; Katra B., Klupa T., Skupien J., Szopa M., Nowak N., Borowiec M. et al. Dipeptidyl peptidase‐IV inhibitors are efficient adjunct therapy in HNF1A maturity‐onset diabetes of the young patients – report of two cases. Diabetes Technol Ther. 2010;12(4):313–316. doi:10.1089/dia.2009.0159.; Østoft S.H. Incretin hormones and maturity onset diabetes of the young – pathophysiological implications and anti‐diabetic treatment potential. Dan Med J. 2015;62(9):B4860. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26324089.; Østoft S.H., Bagger J.I., Hansen T., Hartmann B., Pedersen O., Holst J.J. et al. Postprandial incretin and islet hormone responses and dipeptidyl‐peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. European Journal of Endocrinology. 2015;173(2):205–215. doi:10.1530/EJE-15-0070.; Stride A., Ellard S., Clark P., Shakespeare L., Slzmann M., Shepherd M. et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care. 2005;28(7):1751–1756. doi:10.2337/diacare.28.7.1751.; Hohendorff J., Szopa M., Skupien J. A single dose of dapagliflozin, an SGLT- 2 inhibitor, induces higher glycosuria in GCK- and HNF1A-MODY than in type 2 diabetes mellitus. Endocrine. 2017;57(2):272–279. doi:10.1007/s12020-017-1341-2.; Tatli Z.U., Direk G., Hepokur M., Hatipoğlu N., Akin L., Kendirci M., Kurtoglu S. Continuous Glucose Monitoring Results of Our Cases with MODY Type 2 Diabetes. ESPE Abstracts. 2018;89:P3-P124. Avalable at: http://abstracts.eurospe.org/hrp/0089/hrp0089p3-p124.; Bacon S., Kyithar M.P., Condron E.M., Vizzard N., Burke M., Byrne M.M. Prolonged Episodes of Hypoglycaemia in HNF4A-MODY Mutation Carriers with IGT. Evidence of Persistent Hyperinsulinism into Early Adulthood. Acta Diabetologica. 2016;53:965–972. doi:10.1007/s00592-016-0890-9.
-
7Academic Journal
Συγγραφείς: Novytska, A. V.
Πηγή: Medicine of Ukraine; № 3(199) (2016); 51-58
Лекарства Украины; № 3(199) (2016); 51-58
Ліки України; № 3(199) (2016); 51-58Θεματικοί όροι: цукровий діабет 2-го типу, сімейна медицина, лікування цукрового діабету, пероральні цукрознижуючі препарати, глімепірид, 616.379-008.64-082-056.76, type 2 diabetes mellitus, family medicine, treatment of diabetes, oral hypoglycemic drugs glimepiride, сахарный диабет 2-го типа, семейная медицина, лечение сахарного диабета, пероральные сахароснижающие препараты, глимепирид, 3. Good health
Περιγραφή αρχείου: application/pdf
-
8Academic Journal
Συγγραφείς: L. A. Ruyatkina, D. S. Ruyatkin, A. K. Ovsyannikova
Πηγή: Медицинский совет, Vol 0, Iss 4, Pp 100-109 (2016)
Θεματικοί όροι: вариабельность гликемии, hypoglycemic agents, сахароснижающие препараты, острый коронарный синдром, инкретиновые препараты, acute coronary syndrome, 3. Good health, сахарный диабет 2-го типа, 03 medical and health sciences, 0302 clinical medicine, glycemic variability, gliptins, глиптины, Medicine, type 2 diabetes, incretins
Σύνδεσμος πρόσβασης: https://www.med-sovet.pro/jour/article/download/86/86
https://doaj.org/article/8fc202e4dcf64a7eaa6be1a19766cb99
https://cyberleninka.ru/article/n/problemy-saharosnizhayuschey-terapii-u-patsientov-s-saharnym-diabetom-pri-ostrom-koronarnom-sindrome/pdf
https://cyberleninka.ru/article/n/problemy-saharosnizhayuschey-terapii-u-patsientov-s-saharnym-diabetom-pri-ostrom-koronarnom-sindrome
https://www.med-sovet.pro/jour/article/view/86
https://www.med-sovet.pro/jour/article/download/86/86 -
9Academic Journal
Συγγραφείς: Casian, V.P., Şeremet, A., Alexa, Z.G., Harea, D.G.
Πηγή: Sănătate Publică, Economie şi Management în Medicină 81 (3) 36-41
Θεματικοί όροι: diabet zaharat, intensifi care, antidiabetice, insulină, diabetes, intensifi cation, antidiabetics, insulin, сахарный диабет, сахароснижающие препараты, инсулин
Περιγραφή αρχείου: application/pdf
Relation: https://ibn.idsi.md/vizualizare_articol/86026; urn:issn:17298687
Διαθεσιμότητα: https://ibn.idsi.md/vizualizare_articol/86026
-
10Academic Journal
Συγγραφείς: O. M. Kyrychenko, O. I. Leonchenko, O. A. Kyrychenko
Πηγή: Clinical pharmacy; Vol. 19 No. 2 (2015); 14-18
Клиническая фармация; Том 19 № 2 (2015); 14-18
Клінічна фармація; Том 19 № 2 (2015); 14-18Θεματικοί όροι: АТС/DDD методологія, сахарный диабет ІІ типа, пероральні цукрознижувальні препарати, 616.4, АТС/DDD методология, анализ потребления, type ІІ diabetes mellitus, consumption analysis, 3. Good health, ATC/DDD methodology, пероральные сахароснижающие препараты, 03 medical and health sciences, аналіз споживання, 0302 clinical medicine, цукровий діабет ІІ типу, oral hypoglycemic agents, UDC 615.03, УДК 615.03
Περιγραφή αρχείου: application/pdf; application/msword
-
11Academic Journal
Συγγραφείς: M. Sh. Khubutia, O. N. Rzhevskaya, K. E. Lazareva, М. Ш. Хубутия, О. Н. Ржевская, К. Е. Лазарева
Πηγή: Transplantologiya. The Russian Journal of Transplantation; № 2 (2009); 9-14 ; Трансплантология; № 2 (2009); 9-14 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2009-0-2
Θεματικοί όροι: пероральные сахароснижающие препараты, glucose intolerance, tacrolimus, cadaveric renal allotransplantation, pancreatic allotransplantation, glycosylated hemoglobin, oral sugar-lowering drugs, нарушение толерантности к глюкозе, такролимус, аллотрансплантация трупной почки, аллотрансплантация поджелудочной железы, гликолизированный гемоглобин
Περιγραφή αρχείου: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/250/312; Hathaway D.K., Tolley E.A., Blakely M.L. et al. Development of an index to predict post-transplant diabetes mellitus. Clin Transplant 1994;7:330—8.; Friedman E.A., Shyh T., Beyer M.M. et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985;5: 196—202.; Vincenti F., Friman S., Scheuermann E. et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transp 2007;7:1506—14.; Howard A. Management of new-onset diabetes mellitus in the kidney transplant recipient. Medscape Transplant 2004; 14 Jul.; Thomas M.C, Moran J., Mathew T.H. et al. Early peri-operative hyperglycaemia and renal allograft rejection in patients without diabetes. BMC Nephrology 2000;1:1.; Pourmand G., Ebrahimi M.R., Mehrsai A.R., Taheri M. Patient blood glucose levels before and after kidney transplantation. Transplant Proc 2000;32(3):566—8.; Min C., Kang E., Yu S.H. et al. Advanced glycation end products induce apoptosis and pro-coagulant activity in cultured human umbilical vein endothelial cells. Diabetes Res Clin Pract 1999;46(3): 197—202.; Pavlovic D., Van de Winkel M., Van der Auwera B. et al. Effect of interferongamma and glucose on major histo-compatibility complex class I and class II expression by pancreatic beta- and non-beta-cells. J Clin Endocrinol Metab 1997;82(7):2329—36.; Foster K.J., Alberti K.G., Binder C. et al. Lipid metabolites and nitrogen balance after abdominal surgery in man. Br J Surg 1979;66(4):242—5.; Spencer C.M., Goa K.L., Gillis J.C. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997;54: 925—75.; Jindal R.M., Sidner R.A., Milgrom M.L. Post-transplant diabetes mellitus. The role of immunosuppression. Drug Saf 1997;16: 242—57.; Pirsch J.D., Miller J., Deierhoi M.H. et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997;63:977—83.; Cavaille-Coll M.W., Elashoff M.R. Commentary on a comparison of tacrolimus and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1998;65:142—3.; Marchetti P., Navalesi R. The metabolic effects of cyclosporine and tacrolimus. J Endocrinol Invest 2000;23:482—90.; Heisel O., Heisel R., Balshaw R., Keown P. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant 2004;4;583—95.; Jain A., Khanna A., Molmenti E.P. et al. Immunosuppressive therapy. Surg Clin North Am 1999;79:59—76.; Johnson C., Ahsan N., Gonwa T. et al. Randomized trial of tacrolimus in combination with azathioprine or mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000;63;834—41.; Lazzaro C., McKechnie T., McKenna M. Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses. J Nephrol 2002;15:580—8.; Vincenti F., Jensik S.C., Filo R.S. et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002;73:775—82.; Weir M.R., Fink J.C. Risk for post-transplant diabetes mellitus with current immunosuppressive medications. Am J Kidney Dis 1999;34:1—13.; Hirano Y., Fujihira S., Ohara K. et al. Morphological and functional changes of islets of Langherans in FK506-treated rats. Transplantation 1992;53:889—94.; Martin F., Bedoya F.J. Mechanisms of action of cyclosporine A on islet alfa-and beta cells. Effects on cAMP and calcium dependent pathways. Life Sci 1991;49:1915—21.; Redmond J.B., Olson L.K., Armstrong M.B. et al. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 1996;98: 2786—93.; Ishizuka J., Guiuzza K.K., Wassmuth Z. et al. Effects of FK506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islet. Transplantation 1993;56:1486—90.; Noguchi N., Takasawa S., Nata K. et al. Cyclic ADP-ribose binds to FK506 binding protein 12.6 to release calcium++ from islet microsome. J Biol Chem 1997;272:3133—6.; Lanerolle R.D., de Abrew K., Fernando D.J., Sheriff M.H. Posttransplant diabetes in Sri Lanka. Transplant Proc 1996;28:1945—7.; Berwerck S., Kahl A., Bechstein W. et al. Clinical use of the euglicemic hyperinsulinemic clamp for diagnosis of tacrolimusinduced insulin resistance after combined pancreas-kidney transplantation. Transplant Proc 1998;30:1944—5.; Basadonna G., Montorsi F., Dakizaki K., Merrell R.C. Cyclosporine A and islet function. Am J Surg 1988;156:191—3.; Bani Sacchi T., Bani D., Filipponi F. et al. Immunocytochemical and ultra structural changes of islet cells in rats treated longterm with cyclosporine at immunotherapeutic doses. Transplantation 1990;49:982—7.; Van Hoff J.P., Christiaans M.H., Ven Duijnhoven E.M. et al. Glucose metabolic disorder after transplantation. Am J Transplant 2007;7:1435—6.; Ciancio G., Burke G., Gaynor J. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (NEORAL)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004;77:252—8.; Maes B.D., Kuypers D., Messian T. et al. Post-transplan-tation diabetes mellitus in FK506-treated renal transplant recipients: analysis of incidence and risk factors. Transplantation 2001;72:1655—61.; Pagano G., Cavalco-Perin P., Cassader M. et al. An in vivo and in vitro study of the mechanism of prednisoneinduced insulin resistance in healthy subjects. J Clin Invest 1983;72:1814—20.; Shapiro R., Jordan M.L., Scantlebury V.P. et al. A prospective, randomized trial of FK506/prednisone vs FK506/azathioprine/prednisone in renal transplant patients. Transplant Proc 1995;27:814—7.; Christiansen E., Andersen H., Rasmusse K. et al. Pancreatic b-cell function and glucose metabolism in human segmental pancreas and kidney transplantation. Am Physiol Soc 1993;264(3):441—9.; Andrews R.C., Wolker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin Sci 1999;96:513—23.; Henriksen J.E., Alford F., Ward G.M., Beck-Nielsen H. Risk and mechanism for dexamethazone-induced deterioration of glucose tolerance in non-diabetic first degree relatives of NIDDM patients. Diabetologia 1997;40:1439—48.; Hjelmesaeth J., Hartmann A., Kosstad J. et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997;64:979—83.; Jawad F., Rizvi S.A. Post-transplant diabetes mellitus in live-re-lated renal transplantation. Transplant Proc 2000;32:1888.; Boots J.M., Van Duijnhoven E.M., Christiaans M.H. et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002;13:221—7.; Vanrenterghem Y. Strategies to reduce or replace steroid dosing. Transplant Proc 1999;31 (Suppl 8A):7—10.; Christiansen E., Tibell A., Volund A.A. et al. Metabolism of oral glucose in pancreas transplant recipients with normal and impaired glucose tolerance. J Clin Endocrinol Metab 1997;82:2299—307.; Gruessner R.W. Tacrolimus in pancreas transplantation: a multi-center analysis. Tacrolimus Pancreas Study Group. Clin Transplant 1997;11:299—312.; Gruessner R.W., Burke G.W., Stratta R. et al. A multi-center analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996;61:261—73.; Sumrani N.B., Delaney V., Ding Z. et al. Diabetes mellitus after renal transplantation in the cyclosporine era: an analysis of risk factors. Transplantation 1991;51:343—7.; Rao M., Jacob C.K., Shastry J.C. Post-renal transplant diabetes mellitus: a retrospective study. Nephrol Dial Transplant 1992;7:1039—42.; Keen H., Jarret R.J., Mc Cartney P. The ten-year follow-up of the Bedford survey (1962—1972): glucose tolerance and diabetes. Diabetologia 1982;22:73—8.; Vesco L., Busson M., Bedrossian J. et al. Diabetes mellitus after renal transplantation. Transplantation 1996;61:1475—8.; Kasiske B.L., Sneyder J.J., Gilbertson D., Matas A.J. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2002;2(Suppl 3):225.; Knoll G.A., Bell R.C. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. Br Med J 1999;318:1104—7.; Parikh C., Klem P., Wong C., Chan L. Obesity as an independent predictor of posttransplant diabetes mellitus (PTDM). Am J Transplant 2002;2(Suppl 3):420.; De Mattos A.M., Prather J., Al-Uzri A. et al. Autosomal dominant polycystic kidney disease (ADPKD) as risk factor for the development of posttransplant diabetes mellitus (PTDM). Am J Transplant 2002;2:359.; Cosio F.G., Pesavento T.E., Kim S. et al. Patient survival after renal transplantation: IV. Impact of post-transplant diabetes. Kidney Int 2002;62:1440—6.; Revanur V.K., Jardine A.G., Kingsmore D.B. et al. Influence of diabetes mellitus on patients and graft survival in recipients of kidney transplantation. Clin Transplant 2001;15:89—94.; Thomas M.C., Mathew P.H., Russ G.R. et al. Early perioperative glycemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation 2001;72:1321—4.; Klahr S., Levey A.S., Beck G.J. et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N Engl J Med 1994;330:877—84.; Noble N.A., Border W.A. Angiotensin II in renal fibrosis. Should TGF-beta rather than blood pressure be the therapeutic target? Semin Nephrol 1997;17:455—66.; Miles A.M., Sumrani N., Horowitz R. et al. Diabetes mellitus after renal transplantation. Transplantation 1998;65:380—4.; Schneider D.J., Nordt T.K., Sobel B.E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 1993;42:1—7.; Maser R.E., Wolfson S.K. Jr., Ellis D. et al. Cardiovascular disease and arterial calcification in insulin-dependent diabetes mellitus: interrelations and risk factor profiles. Arterioscler Thromb 1991;11:958—65 [Abstract].; Laakso M., Pyorala K., Scarlund H., Voutilainen E. Lipid and lipoprotein abnormalities associated with coronary heart disease in patients with insulin-dependent diabetes mellitus. Arteriosclerosis 1986;6:679— 84 [Abstract].; Raine A.E.G. Cardiovascular complications after renal transplantation. In: P.J. Morris (ed.). Kidney transplantation: principles and practice. Philadelphia: PA, Saunders; 1988. p. 575—601.; Hjelmeseth J., Hartmann A., Midvedt K. et al. Metabolic cardiovascular syndrome after renal Transplantation. Nephrol Dial Transplant 2001;16:1047—52.; Von Kiparsky A., Frei D., Uhlschmid G. et al. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol Dial Transplant 1990;5:220—5.; Chiu M.Y., Sprague S.M., Bruce D.S. et al. Analysis of fracture prevalence in kidneypancreas allograft recipients. J Am Soc Nephrol 1998;9:677—83.; Marchetti P. Strategies for risk reduction and management of post-transplant diabetes mellitus. Transplant Proc 2001;33(Suppl 5A):27—31.; https://www.jtransplantologiya.ru/jour/article/view/250
-
12Academic Journal
Συγγραφείς: P. B. Shorokhova, K. A. Zagorodnikova, V. L. Baranov, N. V. Vorokhobina, Полина Борисовна Шорохова, Ксения Александровна Загородникова, Виталий Леонидович Баранов, Наталья Владимировна Ворохобина
Πηγή: Pharmacogenetics and Pharmacogenomics; № 1 (2018); 9-14 ; Фармакогенетика и фармакогеномика; № 1 (2018); 9-14 ; 2686-8849 ; 2588-0527
Θεματικοί όροι: polymorphism, пероральные сахароснижающие препараты, KCNJ11, ABCC8, TCF7L2, полиморфизм, diabetes mellitus, oral hypoglycemic agents
Περιγραφή αρχείου: application/pdf
Relation: https://www.pharmacogenetics-pharmacogenomics.ru/jour/article/view/41/41; International Diabetes Federation (IDF). IDF Diabetes Atlas. 2017;8th edition: 7-11.; Аметов А.С. Сахарный диабет 2 типа. Проблемы и решения. - М.: ГЭОТАР-Медиа; 2017.; DeFronzo RA. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773-795. DOI:10.2337/db09-9028; Дедов И.И., Шестакова М.В., Аметов А.С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов по инициации и интенсификации сахароснижающей терапии у больных сахарным диабетом 2 типа // Сахарный диабет. - 2011. - Т. 14. - № 4. - С. 6-17.; Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. - 8-й выпуск. - М.: Уп ПРИНТ; 2017. Сахарный диабет. - 2017; - 20(1S). - С.1-112.; Российские клинические рекомендации. Эндокринология / Под ред. И.И. Дедова, Г.А. Мельниченко. - М.: ГЭОТАР-Медиа; 2016. - С. 531-556.; Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care. 2008;31:1-11.; Inzucchi SE, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015 Aug;38(8):e128-129. DOI:10.2337/dc15-0812; Viollet B., Guigas B., Sanz Garcia N., et al. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond). 2012 Mar;122(6): 253-270. DOI:10.1042/CS20110386; Bailey C. J., Wilcock C., Scarpello J. H. Metformin and the intestine. Diabetologia. 2008 Aug;51(8):1552-1553. DOI:10.1007/s00125-008-1053-5; Madiraju AK, Erion DM, Rahimi Y., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014 Jun 26;510(7506):542-546. DOI:10.1038/nature13270; Prager R., Shernthaner G., Graf H. Effect of metformin on peripheral insulin sensitivity innon insulin dependent diabetes mellitus. Diabetes Metab. 1986;12(6):346-350.; Bailey CJ. The current drug treatment landscape for diabetes and perspectives for the future. Clin Pharmacol Ther. 2015 Aug;98(2):170-184. DOI:10.1002/cpt.144; Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. EndocrPract. 2009 Sep-0ct;15(6):540-559. DOI:10.4158/EP.15.6.540; Дедов И.И., Шестакова М.В., Аметов А.С. и др. Консенсус совета экспертов Российской ассоциации эндокринологов (РАЭ) по инициации и интенсификации сахароснижающей терапии СД 2 типа // Сахарный диабет. - 2011. - №1. - С. 95-105.; Вaggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-2157. DOI:10.1053/j.gastro.2007.03.054; Kim W., Egan J. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev. 2008 Dec;60(4):470-512. DOI:10.1124/pr.108.000604; Perfetti R. The role of GLP-1 in the regulation of the islet cell mass. Medscape Diabet Endocrinol. 2004;6(2):134-138.; Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in Type 2 diabetes. Diabetes Metab. 2008 Feb;34 Suppl 2:S65-72. DOI:10.1016/S1262-3636(08)73397-4; Nauck M.A. Incretin-based therapies for Type 2 diabetes mellitus: properties, functions, and clinical implications. Am J. Med. 2011 Jan;124 (1 Suppl):S3-18. DOI:10.1016/j.amjmed.2010.11.002; Weyer C., Bogardus C., Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin Invest. 1999 Sep;104(6):787-94. DOI:10.1172/JCI7231; Клиническая фармакология: национальное руководство / Под ред. Ю.Б. Белоусова, В.Г. Кукеса, В.К. Лепахина, В.И. Петрова. - М.: ГЭОТАР-Медиа; 2009.; Рациональная фармакотерапия заболеваний эндокринной системы и нарушений обмена веществ. 2-е изд. / Под общ. ред. И.И. Дедова, Г.А. Мельниченко. - М.: ГЭОТАР-Медиа; 2013.; Серединин С.Б. Лекции по фармакогенетике. - М.: Издательство МИА; 2004. - С. 12-48.; Сычев Д.А. Фармакогенетическое тестирование: клиническая интерпретация результатов. - М.: 2011. - С. 8-15.; Клиническая фармакогенетика: учебное пособие / Под ред. В.Г. Кукеса, Н.П. Бочкова. - М.: ГЭОТАР-Медиа; 2007.; Aguilar-Bryan L., Bryan J. Molecular biology of adenosine triphosphate - sensitive potassium channels. Endocr Rev. 1999 Apr;20(2):101-135. DOI:10.1210/edrv.20.2.0361; Seino S., Miki T. Physiological and pathophysiological roles of ATP-sensitive K+ channels. ProgBiophys Mol Biol. 2003 Feb;81(2):133-176.; Flanagan SE, Clauin S., Bellanne-Chantelot C., et al. Update of mutations in the genes encoding the pancreatic beta-cell K(ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2009 Feb;30(2):170-180. DOI:10.1002/humu.20838; James C., Kapoor RR, Ismail D., et al. The genetic basis of congenital hyperinsulinism. J. Med Genet. 2009 May;46(5):289-299. DOI:10.1136/jmg.2008.064337; Thomas P., Ye Y., Lightner E. Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet. 1996 Nov;5(11):1809-1812.; Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl J. Med. 2004 Apr 29;350(18):1838-1849. DOI:10.1056/NEJMoa032922; Florez JC, Jablonski KA, Kahn SE, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes. 2007 Feb;56(2):531-536. DOI:10.2337/db06-0966; Lang VY, Fatehi M., Light PE. Pharmacogenomic analysis of ATP-sensitive potassium channels coexpressing the common type 2 diabetes risk variants E23K and S1369A. Pharmacogenet Genomics. 2012 Mar;22(3):206- 214. DOI:10.1097/FPC.0b013e32835001e7; Fatehi M., Raja M., Carter C., et al. The ATP-sensitive K. (+) channel ABCC8 S1369A type 2 diabetes risk variant increases MgATPase activity. Diabetes. 2012 Jan;61(1):241-249. DOI:10.2337/db11-0371; Florez JC, Hirschhorn J., Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet. 2003;4:257-291. DOI:10.1146/annurev.genom.4.070802.110436; Gloyn AL, Hashim Y., Ashcroft SJ, et al. Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with Type 2 diabetes mellitus (UKPDS 53). Diabet Med. 2001 Mar;18(3):206-212.; Nikolac N., Simundic AM, Katalinic D., et al. Metabolic control in type 2 diabetes is associated with sulfonylurea receptor-1 (SUR-1) but not with KCNJ11 polymorphisms. Arch Med Res. 2009 Jul;40(5):387-392. DOI:10.1016/j.arcmed.2009.06.006; Ragia G., Tavridou A., Petridis I., et al. Association of KCNJ11E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes Res Clin Pract. 2012 Oct;98(1):119-124. DOI:10.1016/j.diabres.2012.04.017; Sato R., Watanabe H., Genma R., et al. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas. Pharmacogenomics. 2010 Dec;11(12):1743-1750. DOI:10.2217/pgs.10.135; Li Q., Chen M., Zhang R., et al. KCNJ11 E23K variant is associated with the therapeutic effect of sulphonylureas in Chinese type 2 diabetic patients. Clin Exp Pharmacol Physiol. 2014 Oct;41(10):748-754. DOI:10.1111/1440-1681; Sesti G., Laratta E., Cardellini M., et al. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5’-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. J. Clin Endocrinol Metab. 2006 Jun;91(6):2334-2339. DOI:10.1210/jc.2005-2323; Holstein A., Hahn M., Stumvoll M., et al. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes. Horm Metab Res. 2009 May;41(5):387-390. DOI:10.1055/s-0029-1192019; El-Sisi AE, Hegazy sK, Metwally SS, et. al. Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in egyptian patients with type 2 diabetes. Ther Adv Endocrinol Metab. 2011 Aug;2(4):155-164. DOI:10.1177/2042018811415985; Feng Y., Mao G., Ren X., et al. Ser1369Ala variant in sulfonylurea receptor gene ABCC8 is associated with antidiabetic efficacy of gliclazide in Chinese type 2 diabetic patients. Diabetes Care. 2008 Oct;31(10):1939-1944. DOI:10.2337/dc07-2248; Zhang H., Liu X., Kuang H., et al. Association of sulfonylurea receptor 1genotype with therapeutic response to gliclazide in type 2 diabetes. Diabetes Res Clin Pract. 2007 Jul;77(1):58-61. DOI:10.1016/j.diabres.2006.10.021; Jamaluddin JL, Huri HZ, Vethakkan SR. Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment response in Type 2 diabetes mellitus. Pharmacogenomics. 2016 Jun;17(8):867-881. DOI:10.2217/pgs-2016-0010; Chiang YT, Ip W., Jin T. The role of the Wnt signaling pathway in incretin hormone production and function. Front Physiol. 2012 Jul 12;3:273. DOI:10.3389/fphys.2012.00273; Xiong X., Shao W., Jin T. New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic ß-cells: the involvement of the Wnt signaling pathway effector ß-catenin. Islets. 2012 Nov-Dec;4(6):359-365. DOI:10.4161/isl.23345; Peng S., Zhu Y., L. B., et al. TCF7L2 gene polymorphisms and type 2 diabetes risk: a comprehensive and updated metaanalysis involving 121174 subjects. Mutagenesis. 2013 Jan;28(1):25-37. DOI:10.1093/mutage/ges048; Kirchhoff K., Machicao F., Haupt A., et al. Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia. 2008; 51: 597-601.; Srinivasan S., Kaur V., Chamarthi B., et al. TCF7L2 Genetic Variation Augments Incretin Resistance and Influences Response to a Sulfonylurea and Metformin: The Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH). Diabetes Care. 2018 Mar;41(3):554-561. DOI:10.2337/dc17-1386; Махрова И.А., Глотов О.С., Глебова М.А. и др. Эффективность применения метформина при ожирении и метаболическом синдроме у детей и подростков в зависимости от полиморфизма гена TCF7L2 // Медицинская генетика. - 2012. - 4(118). - С. 29-35.; Pearson ER, Donnelly LA, Kimber C., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 2007 Aug;56(8):2178-2182. DOI:10.2337/db07-0440; Zimdahl H., Ittrich C., Graefe-Mody U., et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia. 2014 Sep;57(9):1869-1875. DOI:10.1007/s00125-014-3276-y
-
13Academic Journal
Συγγραφείς: S. V. Vorob'yev, E. U. Petrovskaya, N. A. Kuz'menko, I. A. Khripun, С. В. Воробьев, Е. Ю. Петровская, Н. А. Кузьменко, И. А. Хрипун
Πηγή: Meditsinskiy sovet = Medical Council; № 16 (2018); 86-92 ; Медицинский Совет; № 16 (2018); 86-92 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2018-16
Θεματικοί όροι: Субетта, macro- and microvascular complications, antidiabetic drugs, Subetta, макро- и микрососудистые осложнения, сахароснижающие препараты
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/2637/2600; Dedov II, Shestakova MV, Benedetti MM, Simon D, Pakhomov I, Galstyan G, NATION study, diabetes research and clinical practice, 2016.; Дедов И.И., Шестакова М.В., Викулова О.К. Сахарный диабет. Федеральный регистр СД. 2017, 20(1): 13-41.; IDF Diabetes Atlas, 7th edition. Brussels: International Diabetes Federation; 2015. Available from: http://www.diabetesatlas.org.; Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ, 2000, 321(7258): 405-12.; Giugliano D, Maiorino MI, Bellastella G, Esposito K. Type 2 diabetes and cardiovascular prevention: the dogmas disputed Endocrine. 2017.; Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes – 2018. American Diabetes Association Diabetes Care Jan, 2018, 41(1): 73-85. doi:10.2337/dc18-S008.; Демидов Н.А., Аванесова Д.И., Андрияшина Е.Г., Капустина Л.А., Мишра О.А., Сафронова Т.Э., Дорофеева Л.Г., Анциферов М.Б. Структура медикаментозной терапии больных сахарным диабетом 2 типа по данным Московского регистра больных сахарным диабетом, 2017.; Мисникова И.В., Древаль А.В., Ковалева Ю.А. Гликированный гемоглобин – основной параметр в контроле сахарного диабета. Сахарный диабет, 2008, 4: 36-39.; Эпштейн О.И. Релиз-активность (современный взгляд на гомеопатию и негомеопатию). М.: Издательство РАМН. 2017, 48.; Epstein O. The spatial homeostasis hypothesis. Symmetry, 2018, 10(4): 103. doi:10.3390/ sym10040103.; Bailbé D, Philippe E, Gorbunov E, Tarasov S, Epstein O, Portha B. The Novel Oral Drug Subetta Exerts an Antidiabetic Effect in the Diabetic Goto-Kakizaki Rat: Comparison with Rosiglitazone. Journal of Diabetes Research, 2013, 13(1): Article ID 763125. doi:10.1155/2013/763125.; Gorbunov EA, Nicoll J, Myslivets AA, Kachaeva EV, Tarasov SA. Subetta Enhances Sensitivity of Human Muscle Cells to Insulin. Bulletin of Experimental Biology and Medicine, 2015, 159(4): 463-465.; Nicoll J, Gorbunov EA, Tarasov SA, Epstein OI. Subetta Treatment Increases Adiponectin Secretion by Mature Human Adipocytes In Vitro. International Journal of Endocrinology, 2013, 2013: 1-4.; Хейфец И.А., Спасов А.А., Воронкова М.П., Дугина Ю.Л., Эпштейн О.И. Изучение гипогликемической активности субетты и росиглитазона на модели стрептозотоцинового диабета у крыс. Бюллетень экспериментальной биологии и медицины, 2012, 153(1): 62-64.; Инструкция по медицинскому применению препарата Субетта https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid = 83f9a6c1-1115-41a2-b329-440652c7954e&t=ef769e67-8063-48a0-9e38-5e4f60e736c3.; Покровский М.В., Кочкаров В.И., Покровская Т.Г., Артюшкова Е.Б., Пашин Е.Н., Даниленко Л.М., Корокин М.В., Белоус А.С., Корокина Л.В., Малыхин В.А., Залозных Я.И., Брусник М.С., Жавберт Е.С. Сравнительное изучение потенциальных эндотелий протекторов и препарата импаза при моделировании дефицита оксида азота. Бюлл. экспер. биол. и мед., 2009, 148(8): 154-157.; Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова, 8-й выпуск, Москва, 2017.
-
14Academic Journal
Συγγραφείς: T. B. Morgunova, V. V. Fadeev
Πηγή: Медицинский совет, Vol 0, Iss 2, Pp 66-69 (2015)
Θεματικοί όροι: сахарный диабет, сахароснижающие препараты, гликемия, инкретин, глюкагоноподобный пептид-1, випидия, diabetes mellitus, hypoglycemic agents, glycemia, incretin, glucagon-like peptide-1, vipidia, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/122; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/35b84b4da44e45aea203c9b7a59c5bcb
-
15Academic Journal
Συγγραφείς: O. M. Smirnova
Πηγή: Медицинский совет, Vol 0, Iss 2, Pp 57-61 (2014)
Θεματικοί όροι: сахарный диабет, неалкогольная болезнь печени, гепатопротекторы, сахароснижающие препараты, diabetes mellitus, non-alcoholic liver disease, hepatoprotectors, hypoglycemic agents, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/509; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/38b28c52292d4701ba120ee76f0e2858
-
16Academic Journal
Συγγραφείς: K. E. Lasareva, O. N. Rzhevskaya, N. V. Zagorodnikova, К. Е. Лазарева, О. Н. Ржевская, Н. В. Загородникова
Πηγή: Transplantologiya. The Russian Journal of Transplantation; Том 9, № 4 (2017); 335-349 ; Трансплантология; Том 9, № 4 (2017); 335-349 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2017-9-4
Θεματικοί όροι: пероральные сахароснижающие препараты, diabetes mellitus, impaired glucose tolerance, tacrolimus, cadaveric kidney allotransplantation, oral hypoglycemic drugs, сахарный диабет, нарушение толерантности к глюкозе, такролимус, аллотрансплантация трупной почки
Περιγραφή αρχείου: application/pdf
Relation: https://www.jtransplantologiya.ru/jour/article/view/201/249; Хубутия М.Ш., Ржевская О.Н., Лазарева К.Е. Нарушение метаболизма глюкозы после трансплантации органов. Трансплантология 2009.(2):9–14.; Davidson J., Wilkinson A., Dantal J., et al. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation. 2003;75(10 Suppl):SS3–SS24. PMID:12775942 DOI:10.1097/01.TP.0000069952.49242.3E; Wilkinson A., Davidson J., Dotta F., et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin. Transplant. 2005;19(3):291–298. PMID:15877787 DOI:10.1111/j.1399-0012.2005.00359.x; Sharif A. Hecking M., de Vries AP., et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am. J. Transplant. 2014;14(9):1992–2000. PMID:25307034 DOI:10.1111/ajt.12850; Cosio F.G., Kudva Y., van der Velde M., et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int. 2005;67(6):2415–2421. PMID:15882287 DOI:10.1111/j.1523-1755.2005.00349.x; Hecking M., Kainz A., Werzowa J., et al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36(9):2763–2771. PMID:23656979 DOI:10.2337/dc12-2441; Vincenti F., Friman S., Scheuermann E., et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am. J. Transplant. 2007;7(6):1506–1514. PMID:17359512 DOI:10.1111/j.1600-6143.2007.01749.x; Chakkera H.A., Weil E.J., Pham P.T., et al. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36(10):1406–1412. PMID:24065856; Hornum M., Jørgensen K.A., Hansen J.M., et al. New-onset diabetes mellitus after kidney transplantation in Denmark. Clin. J. Am. Soc. Nephrol. 2010;5(4):709–716. PMID:20167685 DOI:10.2215/CJN.05360709; Voytovich M.H., Simonsen C., Jenssen T., et al. Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol. Dial. Transplant. 2005;20(2):413–418. PMID:15615809, DOI:10.1093/ndt/gfh641; Werzowa J., Hecking M., Haidinger M., et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebocontrolled clinical trial. Transplantation. 2013;95(3):456–462. PMID:23380864 DOI:10.1097/TP.0b013e318276a20e; Delaunay F., Khan A., Cintra A., et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 1997;1009(8):2094–2098. PMID:9329975 DOI:10.1172/JCI119743; Andrews R.C., Walker B.R. Glucocorticoids and insulin resistance: old hormones, new targets. Clin. Sci. (Lond.). 1999;96(5):513–523. PMID:10209084; Hjelmesaeth J., Hagen L.T., Asberg A., et al. The impact of short-term ciclosporin A treatment on insulin secretion and insulin sensitivity in man. Nephrol. Dial. Transplant. 2007;22(6):1743–1749. PMID:17299003 DOI:10.1093/ndt/gfl820; Gunnarsson R., Lundgren G., Magnusson G., et al. Steroid diabetes-A sign of overtreatment with steroids in the renal graft recipient? Scand. J. Urol. Nephrol. Suppl. 1980;54:135–138. PMID:7013032; Hjelmesaeth J., Hartmann A., Kofstad J., et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation. 1997;64(7):979–983. PMID:9381545; Yang W.C., Chen Y.S, Hsieh W.C., et al. Post-transplant Diabetes Mellitus in Renal Transplant Recipients – Experience in Buddhist Tzu Chi General Hospital. Tzu. Chi. Med. J. 2006;18(3):185–191.; Sumrani N.B., Delaney V., Ding Z.K., et al. Diabetes mellitus after renal transplantation in the cyclosporin era: an analysis of risk factors. Transplantation. 1991;51(2):343–347. PMID:1994525; Boudreaux J.P., McHugh L., Canafax D.M., et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation. 1987;44(3):376–381. PMID:3307061; Von Kiparski A., Fred D., Uhlschmid G., et al. Post-transplant diabetes mellitus in renal allograft recipients: A matchedpair control study. Nephrol. Dial. Transplant. 1990;5(3):220–225. PMID:2113651; Wahlstrom H.E., Akimoto R., Endres D., et al. Recovery and hypersecretion of insulin and reversal of insulin resistance after withdrawal of shortterm cyclosporine treatment. Transplantation. 1992;53(6):1190–1195. PMID:1604471; Gillison S.L., Bartlett S.T., Curry D.L. Inhibition by cyclosporine of insulin secretion – a beta cell-specific alteration of islet tissue function. Transplantation. 1991;52(5):890–895. PMID:1683035; Cosio F.G., Hickson L.J., Griffin M.D., et al. Patient survival and cardiovascular risk after kidney transplantation: the challenge of diabetes. Am. J. Transplant. 2008;8(3):593–599. PMID:18294155 DOI:10.1111/j.1600-6143.2007.02101.x; Hricik D.E., Bartucci M.R., Moir E.J., et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation. 1991;51(2):374–377. PMID:1994531; Cosio F.G., Pesavento T.E., Kim S., et al. Patient survival after renal transplantation: IV. Impact of posttransplant diabetes. Kidney Int. 2002;62(4):1440–1446. PMID:12234317 DOI:10.1111/j.1523-1755.2002.kid582.x; Revanur V.K., Jardine A.G., Kingsmore D.B., et al. Influence of diabetes mellitus on patients and graft survival in recipients of kidney transplantation. Clin. Transplant. 2001;15(2):89–94. PMID:11264633; Thomas M.C., Mathew P.H., Russ G.R., et al. Early perioperative glycemic control and allograft rejection in patients with diabetes mellitus: a pilot study. Transplantation. 2001;72(7):1321–1324. PMID:11602863; Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of diet in renal disease study group. N. Engl. J. Med. 1994;330(13):877–884. PMID:8114857 DOI:10.1056/NEJM199403313301301; Noble N.A., Border W.A. Angiotensin II in renal fibrosis. Should TGFbeta rather than blood pressure be the therapeutic target? Semin Nephrol. 1997;17(5):455–466. PMID:9316214; Sumrani N.B., Delaney V., Ding Z., et al. Diabetes mellitus after renal transplantation in the cyclosporine era : an analysis of risk factors. Transplantation. 1991;51(2):343–347. PMID:1994525; Miles A.M., Sumrani N., Horowitz R., et al. Diabetes mellitus after renal transplantation. Transplantation. 1998;65(3):380–384. PMID:9484755; Lanerolle R.D., de Abrew K., Fernando D.J., Sheriff M.H. Post-renal transplant diabetes in Sri Lanka. Transplant. Proc. 1996;28(10):1945–1947. PMID:8658956; Vesco L., Busson M., Bedrossian J., et al. Diabetes mellitus after renal transplantation. Transplantation. 1996;61(10):1475–1478. PMID:8633374; Raine A.E.G. Cardiovascular complications after renal transplantation. In: ed. Morris P.J. Kidney Transplantation: Principles and Practice. Philadelphia, PA, Saunders, 1988: 575–601.; Schneider D.J., Nordt T.K., Sobel B.E. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes. 1993;42(1):1–7. PMID:8420806; Gruessner R.W. Tacrolimus in pancreas transplantation: A multi-center analysis. Tacrolimus Pancreas Study Group. Clin. Transplant. 1997;11(4):299–312. PMID:16298658 DOI:10.1016/j.transproceed.2005.09.020; Von Kiparsky A., Frei D., Uhlschmid G., et al. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol. Dial. Transplant. 1990;5(3):220–225. PMID:2113651; Chiu M.Y., Sprague S.M., Bruce D.S., et al. Analysis of fracture prevalence in kidney pancreas allograft recipients. J. Am. Soc. Nephrol. 1998;9(4):677–683. PMID:9555671; Marchetti P. Strategies for risk reduction and management of posttransplant diabetes mellitus. Transplant. Proc. 2001;33(5A Suppl):S27–31. PMID:11498202; Roumie C.L., Hung A.M., Greevy R.A., et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann. Intern. Med. 2012;157(9):601–610. PMID:2312885; Thule P.M., Umpierrez G. Sulfonylureas: a new look at old therapy. Curr. Diab. Rep. 2014;14(4):473. PMID:24563333 DOI:10.1007/s11892-014-0473-5; Mocanu M.M., Maddock H.L., Baxter G.F., et al. Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide. Circulation. 2001;103(25):3111–3116. PMID:11425777; Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002;287(3):360–372. PMID:11790216; Turk T., Pietruck F., Dolff S., et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am. J. Transplant. 2006;6(4):842–846. PMID:16539642 DOI:10.1111/j.1600-6143.2006.01250.x; Voytovich M.H., Haukereid C., Hjelmesaeth J., et al. Nateglinide improves postprandial hyperglycemia and insulin secretion in renal transplant recipients. Clin. Transplant. 2007;21(2):246–251. PMID:17425753 DOI:10.1111/j.1399-0012.2006.00634.x; Cusi K., Consoli A., DeFronzo R.A. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 1996;81(11):4059–4067. PMID:8923861 DOI:10.1210/jcem.81.11.8923861; Kolata G.B. The phenformin ban: is the drug an imminent hazard? Science. 1979;203(4385):1094–1096. PMID:424735; Shaw J.S., Wilmot R.L., Kilpatrick E.S. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet. Med. 2007;24(10):1160–1163. PMID:17672860 DOI:10.1111/j.1464-5491.2007.02221.x; Kurian B., Joshi, R., Helmuth A. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract. 2008;14(8):979–984. PMID:19095596, DOI:10.4158/EP.14.8.979; Hecking M., Werzowa J., Haidinger M., et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol. Dial. Transplant. 2013;28(3):550–566. PMID:23328712 DOI:10.1093/ndt/gfs583; Sharif A. Should metformin be our antiglycemic agent of choice posttransplantation? Am. J. Transplant. 2011;11(7):1376–1381. PMID:21564529 DOI:10.1111/j.1600-6143.2011.03550.x; Jenssen T., Hartmann A. Emer ging treatments for post-transplantation diabetes mellitus. Nat. Rev. Nephrol. 2015;11(8):465-477. PMID:25917553 DOI:10.1038/nrneph.2015.59; Bajaj M., Suraamornkul S., Pratipanawatr T., et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes. 2003;52(6):1364–1370. PMID:12765945; Watkins P.B. Idiosyncratic liver injury: challenges and approaches. Toxicol. Pathol. 2005;33(1):1–5. PMID:15805049 DOI:10.1080/01926230590888306; Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007;356(24):2457–2471. PMID:17517853 DOI:10.1056/NEJMoa072761; Luther P., Baldwin D.Jr. Pioglitazone in the management of diabetes mellitus after transplantation. Am. J. Transplant. 2004;49(12):2135–2138. PMID:15575920 DOI:10.1111/j.1600-6143.2004.00613.x; Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705. PMID:17098089 DOI:10.1016/S0140-6736(06)69705-5; Haidinger M., Werzowa J., Hecking M., et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation- a randomized, double-blind, placebo-controlled trial. Am. J. Transplant. 2014;14(1):115–123. PMID:24279801; Lane J.T., Odegaard D.E., Haire C.E., et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation. 2011;92(10):e56–e57. PMID:22067216 DOI:10.1097/TP.0b013e3182347ea4; Strom Halden T.A., Asberg A., Vik K., et al. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation. Nephrol. Dial. Transplant. 2014;29(4):926–933. PMID:24452849 DOI:10.1093/ndt/gft536; Kaakeh Y., Kanjee S., Boone K., Sutton J. Liraglutide-induced acute kidney injury. Pharmacotherapy. 2012;32(1):e7–e11. PMID:22392833 DOI:10.1002/PHAR.1014; Weise W.J., Sivanandy M.S., Block C.A., Comi R.J. Exenatide-associated ischemic renal failure. Diabetes Care. 2009;32(2):e22–e23. PMID:19171732 DOI:10.2337/dc08-1309; Nauck M.A., Del Prato S., DuránGarcía S. et al. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes. Metab. 2014;16(11):1111–1120. PMID:24919526 DOI:10.1111/dom.12327; Yale J.F. Bakris G., Cariou B., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease. Diabetes Obes. Metab. 2014;16(10):1016–1027. PMID:24965700 DOI:10.1111/dom.12348; Kohan D.E., Fioretto P., Tang W., List J.F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 2014;85(4):962–971. PMID:24067431 DOI:10.1038/ki.2013.356; Hornum M., Lindahl J.P., von ZurMuhlen B., et al. Diagnosis, management and treatment of glucometabolic disorders emerging after kidney transplantation: a position statement from the Nordic Transplantation Societies. Transpl. Int. 2013;26(11):1049–1060. PMID:23634804 DOI:10.1111/tri.12112; Yates C. J., Fourlanos S., Hjelmesaeth J., et al. New-onset diabetes after kidney transplantation-changes and challenges. Am. J. Transplant. 2012;12(4):820–828. PMID:22123607 DOI:10.1111/j.1600-6143.2011.03855.x; https://www.jtransplantologiya.ru/jour/article/view/201
-
17Academic Journal
Συγγραφείς: N. A. Chernikova, E. A. Ermakova
Πηγή: Медицинский совет, Vol 0, Iss 9, Pp 70-75 (2013)
Θεματικοί όροι: diabetes mellitus, vascular complications, antihyperglycemic drugs, glibenclamide, сахарный диабет, сосудистые осложнения, сахароснижающие препараты, глибенкламид, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/1106; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/bbdc1f1db45f41b99a7687213c164a62
-
18Academic Journal
Συγγραφείς: A. M. Mkrtumian, S. V. Podachina, M. A. Sviridova, M. Ya. Kanauzov
Πηγή: Медицинский совет, Vol 0, Iss 3-2, Pp 104-110 (2013)
Θεματικοί όροι: сахарный диабет 2-го типа, сахароснижающие препараты, ситаглиптин, diabetes mellitus type 2, hypoglycemic agents, sitagliptin, Medicine
Περιγραφή αρχείου: electronic resource
Relation: https://www.med-sovet.pro/jour/article/view/970; https://doaj.org/toc/2079-701X; https://doaj.org/toc/2658-5790
Σύνδεσμος πρόσβασης: https://doaj.org/article/74aac70b08024b67b205aafb2bcfa434
-
19Academic Journal
Θεματικοί όροι: fixed combination, рациональные комбинации, hypoglycemic drugs, сахароснижающие препараты, комбинированные препараты, сахарный диабет второго типа, diabetes mellitus type II, rational combinations, 3. Good health
Σύνδεσμος πρόσβασης: https://research-journal.org/medical/fiksirovannye-kombinacii-saxarosnizhayushhix-preparatov-standarty-primeneniya-v-rf-ssha-i-evrope/
https://research-journal.org/wp-content/uploads/2018/12/12-1-78.pdf#page=173 -
20Academic Journal
Συγγραφείς: Lyudmila Viktorovna Nedosugova
Πηγή: Сахарный диабет, Vol 5, Iss 3, Pp 28-31 (2002)
Θεματικοί όροι: пероральные сахароснижающие препараты, 03 medical and health sciences, RC620-627, 0302 clinical medicine, показатели гликемии, глюкозотоксичность, Nutritional diseases. Deficiency diseases